PhRMA report reveals nearly 600 drugs in US paediatric pipeline
New research from PhRMA found that in the US, there are almost 600 paediatric medicines in development in over 2,000 clinical trials.
List view / Grid view
News
MHRA suspends license for Picato over concerns of skin malignancy risk
The marketing license for ingenol mebutate gel (Picato) has been suspended by the MHRA due to studies showing an increased risk of skin malignancies from the drug.
FDA grants Priority Review to capmatinib – a targeted lung cancer therapeutic
The US Food and Drug Administration (FDA) has granted Priority Review for capmatinib, a treatment for MET exon 14 skipping mutated non-small cell lung cancer.
Researchers find one dose of HPV vaccine as effective as other regimens
A study investigating the effectiveness of HPV vaccines has revealed that a single dose is as successful at preventing cervical cancer as multiple doses.
NIBRT announces collaboration to improve downstream bioprocessing bottlenecks
A collaboration between the NIBRT and Avantor aims to address issues faced in downstream bioprocessing during buffer preparation for mAbs.
MHRA issues alert for missing information on Atrolak XL tablet leaflets
Side effects revealed during post-marketing experience are not listed on Atrolak XL prolonged-release tablet patient information leaflets, announces the MHRA.
Indian medical device manufacturers need support from multinational companies, says report
A report suggests that instead of taxing medical device imports, the Indian government should offer tax rebates to multinational companies if they partner with domestic device manufacturers.
UK government urges pharma to assess impact of coronavirus on supply chain
The government in the UK has told pharmaceutical businesses to examine the risk that coronavirus poses to the supply chain and retain any stockpiles from Brexit to mitigate shortages.
Novel formulation could provide solution to cancer vaccine shortcomings
Researchers have developed a new formulation for cancer vaccines that could provide a solution to its delivery complications.
Novartis headquarters opens in White City, London
In a formal ceremony, the new headquarters for Novartis has been opened in White City, London, in close proximity to Imperial College London’s research campus.
Solanezumab fails to meet primary endpoint of Phase II/III Alzheimer’s trial
The developers have announced solanezumab failed to show disease-modifying properties against dominantly inherited Alzheimer's disease (DIAD).
The FDA and FTC team up to prevent anti-competitive practices
The two agencies have signed a statement of their intent to combat anti-competitive practices which are preventing the adoption of biosimilars in the US drug market.
Pharma industry calls for GMP agreement between EU and UK
EFPIA, Medicines for Europe and AESGP have called for a Mutual Recognition Agreement on good manufacturing practice in regards to the future relationship between the UK and the EU.
BTK inhibitor meets primary endpoint in Phase IIb trial treating MS
According to its developers, SAR442168 significantly reduced the appearance of new gadolinium (Gd)-enhancing T1-hyperintense brain lesions in the 120 trial patients.
Anti-counterfeit drugs packaging market growing at 13.2 percent CAGR
Research has found that technological innovation and legislation are to drive the growth of the global anti-counterfeit packaging market.
